Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancers at EORTC-NCI-AACR Symposium Aeterna Zentaris Inc. AEZS-108, a novel hybrid molecule made up of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, is normally in a Phase 2 trial in advanced endometrial levitra generic . To find out more on the trial, head to AEZS-108 is the first intravenous drug in a clinical research that directs the chemotherapy agent particularly to luteinizing hormone-releasing hormone -receptor expressing tumors, leading to more targeted treatment with much less damage to healthy tissue. AEZS-108, in a Stage 2 trial in advanced ovarian cancer also, has been granted orphan-medication designation by the U.S.
today announced it has already reached its objective of recruiting 500 sufferers for its pivotal Phase 3 ZoptEC clinical study with zoptarelin doxorubicin in women with advanced, metastatic or recurrent endometrial cancer. The trial is being conducted in over 120 sites in North America, Europe and Israel. The principal efficacy endpoint can be improvement in general survival. A second interim analysis is anticipated during Q4, 2015 at 192 occasions approximately, with the final analysis prepared at an anticipated 384 events. The trial is expected to be completed by the finish of 2016. Related StoriesOvarian cancer patients with a brief history of oral contraceptive use have got better outcomesViralytics enters into scientific trial collaboration contract with MSDMD Anderson study reveals why chemotherapy medications not effective for many pancreatic cancer patientsDavid A.